Related Experiment Videos

Are beta-blockers needed in patients receiving spironolactone for severe chronic heart failure? An analysis of the

Henry Krum1, Paul Mohacsi, Hugo A Katus

  • 1Monash University, Melbourne, Australia. henry.krum@med.monash.edu.au

American Heart Journal
|December 22, 2005
PubMed

Insights

Beta-blockers like carvedilol provide benefits in severe chronic heart failure (CHF) even when patients also take aldosterone antagonists such as spironolactone. This combination therapy is safe and effective for improving outcomes in CHF patients.

Area of Science:

  • Cardiology
  • Pharmacology
  • Internal Medicine

Background:

  • Beta-blockers and aldosterone receptor antagonists are established treatments for severe systolic chronic heart failure (CHF).
  • The added benefit of beta-blockers in patients already on aldosterone antagonists was previously unclear.

Purpose of the Study:

  • To investigate the additional benefit of beta-blockers (carvedilol) in patients with severe CHF already receiving aldosterone antagonists (spironolactone).

Main Methods:

  • Post hoc analysis of the COPERNICUS study involving 2289 patients with severe CHF.
  • Patients were subgrouped based on baseline spironolactone use.
  • Carvedilol's efficacy was compared to placebo across predefined endpoints.

Main Results:

  • Carvedilol demonstrated similar beneficial effects on mortality and hospitalization rates regardless of spironolactone use.
  • Hazard ratios for all-cause mortality, death or CHF hospitalization, and death or cardiovascular hospitalization were consistent across subgroups.
  • Safety and tolerability of carvedilol were also similar in both groups.

Conclusions:

  • Carvedilol is clinically effective in severe CHF patients when added to spironolactone and other standard therapies.
  • Spironolactone does not eliminate the need for beta-blockade to counteract sympathetic activation in severe CHF.
Abstract

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...